Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

福克斯 医学 奥沙利铂 危险系数 氟尿嘧啶 结直肠癌 内科学 临床终点 放化疗 养生 全直肠系膜切除术 外科 化疗 随机对照试验 肿瘤科 癌症 置信区间
作者
Yong Sang Hong,Sun Young Kim,Ji Sung Lee,Byung‐Ho Nam,Kyu‐pyo Kim,Jeong Eun Kim,Young Suk Park,Joon Oh Park,Ji Yeon Baek,Tae‐You Kim,Keun‐Wook Lee,Joong Bae Ahn,Seok‐Byung Lim,Chang Sik Yu,Jin Cheon Kim,Seong Hyeon Yun,Jong Hoon Kim,Jin‐hong Park,Hee Chul Park,Kyung Hae Jung
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:37 (33): 3111-3123 被引量:174
标识
DOI:10.1200/jco.19.00016
摘要

PURPOSE We evaluated the role of oxaliplatin as adjuvant chemotherapy in patients with rectal cancer who received preoperative chemoradiotherapy (CRT) with fluoropyrimidine monotherapy and total mesorectal excision (TME). METHODS The ADORE trial (adjuvant oxaliplatin in rectal cancer) is a multicenter, randomized trial in patients with postoperative ypStage II (ypT3-4N0) or III (ypT any N1-2) rectal cancer after fluoropyrimidine-based preoperative CRT and TME. Patients were randomly assigned (1:1) to receive adjuvant chemotherapy either with FL (fluorouracil 380 mg/m 2 and leucovorin 20 mg/m 2 ) or FOLFOX (oxaliplatin 85 mg/m 2 , leucovorin 200 mg/m 2 , and fluorouracil bolus 400 mg/m 2 on day 1, fluorouracil infusion 2,400 mg/m 2 for 46 hours). Stratification factors included ypStage and participating center. Primary end point was disease-free survival (DFS). RESULTS A total of 321 patients were enrolled between November 19, 2008, and June 12, 2012. Six-year DFS rates were 68.2% in the FOLFOX arm versus 56.8% in the FL arm, with a stratified hazard ratio of 0.63 (95% CI, 0.43 to 0.93; P = .018) by intention-to-treat analysis. In the subgroup analysis for DFS, FOLFOX was favorable versus FL in patients with ypStage III, ypN1b, ypN2, high-grade histology, minimally regressed tumor, and an absence of lymphovascular or perineural invasion. Six-year overall survival rate was 78.1% in the FOLFOX arm versus76.4% in the FL arm (hazard ratio, 0.73; 95% CI, 0.45 to 1.19; P = .21). In the subgroup analysis for OS, FOLFOX was favorable versus FL in patients with ypN2 and minimally regressed tumor. CONCLUSION Adjuvant FOLFOX improved DFS in patients with rectal cancer with ypStage II and III disease after preoperative CRT. Adjuvant FOLFOX may be considered on the basis of the postoperative pathologic stage in those who received preoperative CRT and TME.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI65的应助被han采纳,获得10
1秒前
感动的亦云完成签到,获得积分10
1秒前
LTShawn完成签到,获得积分10
1秒前
1秒前
在水一方的应助被好hshs采纳,获得10
1秒前
molihuakai的应助被舒服的臧凯采纳,获得10
1秒前
六六柳柳发布了新的文献求助10
2秒前
烟花的应助被科研通管家采纳,获得10
2秒前
JamesPei的应助被科研通管家采纳,获得10
2秒前
molihuakai的应助被杨茜然采纳,获得10
2秒前
丘比特的应助被科研通管家采纳,获得10
2秒前
2秒前
2秒前
Owen的应助被科研通管家采纳,获得10
2秒前
李健的应助被科研通管家采纳,获得10
2秒前
星辰大海的应助被科研通管家采纳,获得30
2秒前
乐观的晓啸关注了科研通微信公众号
2秒前
MMP驳回了思源的应助
2秒前
丘比特的应助被科研通管家采纳,获得10
2秒前
Lisa的应助被科研通管家采纳,获得10
3秒前
田様的应助被科研通管家采纳,获得10
3秒前
fan的应助被科研通管家采纳,获得10
3秒前
李爱国的应助被科研通管家采纳,获得10
3秒前
充电宝的应助被科研通管家采纳,获得10
3秒前
yxw发布了新的文献求助10
3秒前
3秒前
3秒前
yi的应助被科研通管家采纳,获得10
3秒前
FashionBoy的应助被科研通管家采纳,获得10
4秒前
烟花的应助被科研通管家采纳,获得10
4秒前
小猛人发布了新的文献求助10
4秒前
Ava的应助被科研通管家采纳,获得10
4秒前
4秒前
王博涵发布了新的文献求助10
5秒前
Q52发布了新的文献求助10
5秒前
5秒前
5秒前
冷静白山发布了新的文献求助10
6秒前
彭于晏的应助被周一采纳,获得10
6秒前
星辰大海的应助被周一采纳,获得10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193925
求助须知:如何正确求助?哪些是违规求助? 9579945
关于积分的说明 21868504
捐赠科研通 7793568
什么是DOI,文献DOI怎么找? 3437462
关于科研通互助平台的介绍 2560923
邀请新用户注册赠送积分活动 2484250